{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:34:41Z","timestamp":1792427681748,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Eculizumab, a terminal complement inhibitor, prevents thrombotic microangiopathy (TMA) and multiorgan damage in hemolytic uremic syndrome (HUS). We evaluated its efficacy and safety in pediatric patients with TMA sub-types: atypical HUS (aHUS), Shiga toxin-producing <jats:italic>Escherichia coli<\/jats:italic> (STEC)-HUS, and transplant-associated TMA (TA-TMA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included all pediatric patients treated with eculizumab for HUS at Schneider Children\u2019s Medical Center (2011\u20132020), including those with pre-existing end-stage kidney disease. Clinical and laboratory parameters were analyzed over 28\u00a0weeks. The primary endpoint was achievement of complete TMA response, defined by sustained normalization of hematologic parameters and renal function. Secondary endpoints included TMA event-free status and additional clinical improvements.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-four pediatric patients (median age 5.8\u00a0years) were included: 13 with aHUS, 5 with STEC-HUS, and 6 with TA-TMA. A complete TMA response was achieved in 12 (50%) of the patients overall: 7 (54%) with aHUS, 3 (60%) with STEC-HUS, and 2 (33%) with TA-TMA. TMA event-free status was reached in 15 (63%) patients. Significant improvements were observed in platelet count (63%), lactate dehydrogenase levels (76% within the first\u00a0week), hemoglobin (60%), and estimated glomerular filtration rate (79%); while CH-50 levels decreased. No severe adverse events were attributed to eculizumab. Chronic kidney disease stage improved for 17 (90%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The efficacy and safety of eculizumab for three TMA subtypes in pediatric patients potentially expands its therapeutic applications. The complete TMA response rate in aHUS supports eculizumab as a first-line use, while the response rate in STEC-HUS suggests potential efficacy beyond eculizumab\u2019s primary indication. The early hematologic responses and reduced CH-50 levels confirm the role of eculizumab complement-mediated HUS and underscore the need for further research in TA-TMA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1535407","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:47:41Z","timestamp":1743785261000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center"],"prefix":"10.3389","volume":"16","author":[{"given":"Naama","family":"Lax","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Davidovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Bernfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.34067\/KID.0000000000000061","article-title":"Chemotherapy-associated thrombotic microangiopathy","volume":"4","author":"Aklilu","year":"2023","journal-title":"Kidney360"},{"key":"B2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000505401","article-title":"Hemolytic uremic syndrome: a contemporary pediatric experience","volume":"144","author":"Alfandary","year":"2020","journal-title":"Nephron"},{"key":"B3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MNH.0b013e3283378f25","article-title":"Thrombotic microangiopathy: new insights","volume":"19","author":"Benz","year":"2010","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/microorganisms7010015","article-title":"Complement activation contributes to the pathophysiology of Shiga toxin-associated hemolytic uremic syndrome","volume":"7","author":"Buelli","year":"2019","journal-title":"Microorganisms"},{"key":"B5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3265\/Nefrologia.pre2012.Nov.11781","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document","volume":"35","author":"Campistol","year":"2013","journal-title":"Nefrologia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"601.e1","DOI":"10.1016\/j.jtct.2024.03.019","article-title":"Use of eculizumab in pediatric patients with high-risk transplantation-associated thrombotic microangiopathy: outcomes and risk factors associated with response and survival. A retrospective study on behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)","volume":"30","author":"Carabante","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.2020081224","article-title":"IgM autoantibodies to complement factor H in atypical hemolytic uremic syndrome","volume":"32","author":"Cugno","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1053\/j.ajkd.2009.08.011","article-title":"Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation","volume":"55","author":"Davin","year":"2010","journal-title":"Am. J. kidney Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1076029615599439","article-title":"Eculizumab in transplant-associated thrombotic microangiopathy","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin. Appl. Thrombosis\/Hemostasis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fped.2019.00133","article-title":"Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management","volume":"7","author":"Dvorak","year":"2019","journal-title":"Front. Pediatr."},{"key":"B12","volume-title":"Clinical pharmacology","year":""},{"key":"B13","volume-title":"IBM micromedex solutions","year":""},{"key":"B14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am. J. kidney Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","article-title":"Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin\u2013related hemolytic and uremic syndrome: a randomized, placebo-controlled trial","volume":"34","author":"Garnier","year":"2023","journal-title":"J. Am. Soc. Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00467-018-4112-2","article-title":"A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement","volume":"34","author":"Giordano","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201ckidney disease: improving global outcomes\u201d(KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10157-018-1610-2","article-title":"Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic\u2013uremic syndrome in Japan: interim analysis of post-marketing surveillance","volume":"23","author":"Ito","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation\u2013associated TMA","volume":"143","author":"Jodele","year":"2024","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.kint.2016.07.002","article-title":"Complement contributes to the pathogenesis of Shiga toxin\u2013associated hemolytic uremic syndrome","volume":"90","author":"Karpman","year":"2016","journal-title":"Kidney Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00467-010-1555-5","article-title":"Genetics and complement in atypical HUS","volume":"25","author":"Kavanagh","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/asheducation-2011.1.15","article-title":"Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations","volume":"2011","author":"Kavanagh","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3390\/ijms24021159","article-title":"Transplant-associated thrombotic microangiopathy in the context of allogenic hematopoietic stem cell transplantation: where we stand","volume":"24","author":"Lazana","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/hematology.2024000545","article-title":"Transplant-associated TMA: the conundrum of diagnosis and treatment","volume":"2024","author":"Li","year":"2024","journal-title":"Hematology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J. rare Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1182\/bloodadvances.2021006523","article-title":"Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT","volume":"6","author":"Mizuno","year":"2022","journal-title":"Blood Adv."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/ndt\/gfz158","article-title":"Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study","volume":"35","author":"Monet-Didailler","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic\u2013uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00467-018-3903-9","article-title":"Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study","volume":"33","author":"Percheron","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molimm.2013.11.009","article-title":"Interaction of Shiga toxin 2 with complement regulators of the factor H protein family","volume":"58","author":"Poolpol","year":"2014","journal-title":"Mol. Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e003573","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ open"},{"key":"B43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European society for blood and marrow transplantation, American society for transplantation and cellular therapy, Asia-Pacific blood and marrow transplantation group, and center for international blood and marrow transplant research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"B44","first-page":"1663","volume-title":"Eculizumab therapy for atypical hemolytic uremic syndrome (aHUS) in pediatric patients: efficacy and safety outcomes from a retrospective study","author":"Simonetti","year":"2011"},{"key":"B45","year":"2019"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.3390\/jcm10143034","article-title":"The syndromes of thrombotic microangiopathy: a critical appraisal on complement dysregulation","volume":"10","author":"Timmermans","year":"2021","journal-title":"J. Clin. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00467-018-4025-0","article-title":"Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome","volume":"34","author":"Walsh","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.3389\/fimmu.2020.564647","article-title":"Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis","volume":"20","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MNH.0b013e32833aff4a","article-title":"Thrombotic microangiopathies: new insights and new challenges","volume":"19","author":"Zipfel","year":"2010","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B50","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat. Rev. Nephrol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1535407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:47:45Z","timestamp":1743785265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1535407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":51,"alternative-id":["10.3389\/fphar.2025.1535407"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1535407","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"article-number":"1535407"}}